Latest News

Artwork can make a remarkable difference without requiring a complete redesign. The Simon Bull Because of You Belgian Wall Tapestry combines expressive flo
Via Talk Markets · September 20, 2026
The fund's wins came by double-digit margins -- and its two losses were about twice as deep as the market's.
Via The Motley Fool · September 20, 2026
Fifth Third Bancorp (NASDAQ:FITB) said it is tracking toward the favorable ends of its third-quarter guidance ranges following the completion of its Comerica conversion over Labor Day weekend, with executives citing stronger deposit growth, stable customer retention and expense savings that are arri
Via MarketBeat · September 20, 2026
Auto parts and accessories retailer AutoZone (NYSE:AZO) will be reporting earnings this Tuesday before the bell. Here’s what you need to know. AutoZone misse...
Via StockStory · September 20, 2026
RV manufacturer Thor Industries (NYSE:THO) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know. THOR Indu...
Via StockStory · September 20, 2026
Homebuilder KB Home (NYSE:KBH) will be reporting results this Tuesday after market close. Here’s what investors should know. KB Home beat analysts’ revenue e...
Via StockStory · September 20, 2026
Office furniture manufacturer MillerKnoll (NASDAQ:MLKN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know. Mi...
Via StockStory · September 20, 2026
7M là địa chỉ được nhiều người hâm mộ bóng đá tìm đến khi có nhu cầu theo dõi tỷ số và kết quả các trận đấu trực tuyến. Nền tảng tập trung tổng hợp nhiều t
Via Talk Markets · September 20, 2026

Obtaining the proper contractor license is an essential step for construction professionals planning to operate legally in Maryland. The state regulates ho
Via Talk Markets · September 20, 2026
NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.
Speaking at t
Via MarketBeat · September 20, 2026
Arm trades at a 125x forward P/E versus ASML's 27.9x, yet both command premium valuations for their monopolistic positions in mobile and chip manufacturing, respectively.
Via The Motley Fool · September 20, 2026
Don't let the prices of the past discourage you from today's opportunities.
Via The Motley Fool · September 20, 2026
The media may hype up passive income, but buying and holding appreciating assets is the better move over the long haul.
Via The Motley Fool · September 20, 2026
The payout has grown every year since 2012 -- but the quarterly payments are uneven, and the growth has slowed.
Via The Motley Fool · September 20, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform.
Kha
Via MarketBeat · September 20, 2026
The market has a history of reacting the wrong way to economic data, but that doesn't mean you can ignore it.
Via The Motley Fool · September 20, 2026
Hyperliquid may be soaring, but how much longer can it hold on to its market-leading position?
Via The Motley Fool · September 20, 2026
With resilient businesses, solid financial performance, and visible growth opportunities, these five TSX stocks offer compelling opportunities for long-term investors.
Via The Motley Fool · September 20, 2026
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company’s mental health treatment pipeline.
Speaki
Via MarketBeat · September 20, 2026
Loblaw is a core holding candidate for a long-term TFSA. Canadians can consider dollar-cost averaging into a position over time to reduce market-timing risk.
Via The Motley Fool · September 20, 2026
The investment bank's stock is in a prime position to head higher.
Via The Motley Fool · September 20, 2026
Canada’s dividend pioneer is the ultimate anchor stock and forever holding in a TFSA.
Via The Motley Fool · September 20, 2026
Nvidia is guiding for 70% top-line growth in its next fiscal year, but the chipmaker has regularly proven too conservative with its guidance in the past.
Via The Motley Fool · September 20, 2026
The software maker is growing faster than ever, yet its shares sit about where they were a year ago. So is the stock finally reasonably priced?
Via The Motley Fool · September 20, 2026
The unlocking of SpaceX shares is reshaping the communications sector.
Via The Motley Fool · September 20, 2026
Aurora Innovation (NASDAQ:AUR) is preparing to expand its autonomous-trucking operations through a second-generation hardware rollout, a planned transition toward a driver-as-a-service model and additional manufacturing relationships, Co-founder and CEO Chris Urmson said at the Morgan Stanley Laguna
Via MarketBeat · September 20, 2026
The sale of 5,578 shares appears to be a routine transaction.
Via The Motley Fool · September 20, 2026
Yields are rising, and investors are selling REITs, opening up an opportunity to buy reliable, high-yield dividend stocks for long-term investors.
Via The Motley Fool · September 20, 2026
It's one of four key sector holdings in the company's portfolio.
Via The Motley Fool · September 20, 2026
This expensive quantum computing stock isn't growing as fast as it seems.
Via The Motley Fool · September 20, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
Chumi Khurana, senior vice president of U.S. Oncology
Via MarketBeat · September 20, 2026
The index has climbed in 34 of the last 41 fourth quarters. The seven misses are the part worth studying.
Via The Motley Fool · September 20, 2026
Coca-Cola isn't cheap, but it is executing well in a difficult market and has an incredible dividend history.
Via The Motley Fool · September 20, 2026
Investors are growing increasingly concerned about AI-powered threats.
Via The Motley Fool · September 20, 2026
Pfizer's rebound is well underway.
Via The Motley Fool · September 20, 2026
SpaceX stock has rebounded nicely since its prior sell-off, but can the momentum last until its next earnings report?
Via The Motley Fool · September 20, 2026
Meta has fallen behind the other frontier labs recently, but that may have changed with the introduction of the Muse app.
Via The Motley Fool · September 20, 2026
WW International (NASDAQ:WW) executives outlined the company’s efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.
Speaking at Morgan Stanley’s healthcare conference,
Via MarketBeat · September 20, 2026
Looking back at how five stocks picked specifically to beat the market over just the next year have now fared 10 years later.
Via The Motley Fool · September 20, 2026
The business multiplied over the decade. The stock's price-to-earnings multiple mostly didn't.
Via The Motley Fool · September 20, 2026
Arista Networks and Vertiv Holdings give investors two long-term ways to play the AI boom beyond the crowded chip trade.
Via The Motley Fool · September 20, 2026
DoorDash and Viking are leaders in delivery and cruises, offering investors growth at a reasonable price.
Via The Motley Fool · September 20, 2026
After decades of spinoffs and separations of various parts, GE Aerospace is now trending toward integration.
Via The Motley Fool · September 20, 2026
A look at what would happen if history repeats itself.
Via The Motley Fool · September 20, 2026
Online slot games have become a familiar form of digital entertainment for adults who enjoy casino-style gaming. With mobile-friendly platforms, simple int
Via Talk Markets · September 20, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX.
Zii
Via MarketBeat · September 20, 2026
Fashion for men continues to evolve, but comfort and versatility remain two of the most important qualities people look for when choosing everyday clothing
Via Talk Markets · September 20, 2026
The Canary Staked TRX ETF could be well timed if the Tron network continues growing.
Via The Motley Fool · September 20, 2026

Yesterday the U.S. Fed raised interest rates for the first time in three years. This was not unexpected. What might it mean for medium-term gold and silver
Via Talk Markets · September 20, 2026
SK Hynix boasts a 44% net margin and trades at 5.8x forward P/E, while AMD commands a 63x multiple despite stronger growth.
Via The Motley Fool · September 20, 2026